CoChat

The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis

Yang, Zheng-sheng, Lin, Ning-ning, Li, Li, Li, Yang · 2016 · Clinical Reviews in Allergy & Immunology

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

TNF inhibitors have been used in psoriasis (Pso) and psoriatic arthritis (PsA), which were associated with increased risk of cardiac and cerebrovascular events. However, whether TNF inhibitors reduce cardiovascular event is still unclear. Therefore, we aimed to evaluate the effect of TNF inhibitors on adverse cardiovascular events (CVEs) in Pso with or without PsA. We undertook a meta-analysis of clinical trials identified in systematic searches of MEDLINE, EMBASE, Wanfang database, Cochrane Database, and Google scholar through December 31, 2015. Five studies (49,795 patients) were included. Overall, compared with topical/photo treatment, TNF inhibitors were associated with a significant lower risk of CVE (RR, 0.58; 95 % CI, 0.43 to 0.77; P < 0.001; I (2) = 66.2 %). Additionally, compared with methotrexate (MTX) treatment, risk of CVE was also markedly decreased in the TNF inhibitor group (RR, 0.67; 95 % CI, 0.52 to 0.88; P = 0.003; I (2) = 9.3 %). Meanwhile, TNF inhibitors were linked to reduced incidence of myocardial infarction compared with topical/photo or MTX treatment (RR, 0.73; 95 % CI, 0.59 to 0.90; P = 0.003; I (2) = 56.2 % and RR, 0.65; 95 % CI, 0.48 to 0.89; P = 0.007; I (2) = 0.0 %, respectively). Furthermore, there was a trend of decreased rate of mortality in the TNF inhibitor group compared with other therapy (RR, 0.90; 95 % CI, 0.54 to 1.50; P = 0.68; I (2) = 70.9 %). TNF inhibitors appear to have net clinical benefits with regard to adverse cardiovascular events in Pso and/or PsA. Rigorous randomized controlled trials will need to evaluate whether TNF inhibitors truly result in reduction of cardiovascular diseases.

Overview

Integrity signals

Registry

Crossref · 10.1007/s12016-016-8560-9

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

See all 125

Metadata

Authors
Yang, Z.-S., Lin, N.-N., Li, L., & Li, Y.
Affiliations
First Hospital of Qinhuangdao (CN)
ORCID
Li, Li
Venue
Clinical Reviews in Allergy & Immunology
Published
2016-06-14
Volume
51
Issue
2
Pages
240-247
ISSN
  • 1080-0549 (ISSN-L)
  • 1559-0267
OpenAlex
W2433359723
Cited by
123
References
28
Citations by year
2026: 8 · 2025: 18 · 2024: 14 · 2023: 11 · 2022: 15 · 2021: 18 · 2020: 10 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 1
FWCI
5.85
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Reviews in Allergy & Immunology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
TNF-alpha inhibitors, psoriasis, psoriatic arthritis, cardiovascular events, myocardial infarction, methotrexate, mortality, adverse drug reactions, cardiovascular risk
MeSH terms
Tumor Necrosis Factor Inhibitors, Antibodies, Monoclonal, Cardiovascular Diseases, Clinical Trials as Topic, Humans, Methotrexate, Psoriasis, Arthritis, Psoriatic, Incidence, Odds Ratio, Antirheumatic Agents, Patient Outcome Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis. https://app.cochat.ai/papers/10.1007/s12016-016-8560-9
The paper
Yang, Z.-S., Lin, N.-N., Li, L., & Li, Y. (2016). The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis. Clinical Reviews in Allergy & Immunology. https://doi.org/10.1007/s12016-016-8560-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.